ClinicalTrials.gg
CompletedNCT01684423EINSTEINJuniorUpdated Sep 21, 2017Results posted

Oral Rivaroxaban in Children With Venous Thrombosis

A Phase 2 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Active comparator in Venous Thrombosis, sponsored by Bayer. Completed at 59 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-09-21.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing rivaroxaban in Venous Thrombosis — 5 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Venous Thrombosis.

Enrollment
27th of 36
64 · median 120
Started
2013
with 2 others
Phase 2
4 of 36
none open now
Registered
8th of 36
by date
Lead sponsor
11 of 36
Bayer

Among the 36 studies testing rivaroxaban in Venous Thrombosis, this one is the 27th largest by enrollment, is one of 3 that started in 2013, is one of 4 in phase 2, and was the 8th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 36 studies testing rivaroxaban in Venous Thrombosis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing rivaroxaban in Venous Thrombosis, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. There will also be a check for bleeding and worsening of blood clots.

03

Conditions studied

  • Venous Thrombosis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 6 to \< 18 years with documented symptomatic or asymptomatic venous thrombosis treated for at least 2 months or, in case of catheter related thrombosis, treated for at least 6 weeks with LMWH (low molecular weight heparin), , fondaparinux and/or VKA (vitamin K antagonist).
  • provided and, if applicable, child assent provided

Exclusion criteria

Exclusion Criteria:

  • Active bleeding or high risk for bleeding contraindicating anticoagulant therapy
  • Symptomatic progression of venous thrombosis during preceding anticoagulant treatment
  • Planned invasive procedures, including lumbar puncture and removal of non peripherally placed central lines during study treatment
  • An estimated (eGFR) \< 30 mL/min/1.73 m2
  • Hepatic disease which is associated with coagulopathy leading to a bleeding risk or > 5x upper level of normal () or total > 2x ULN with direct bilirubin > 20% of the total
  • count \< 50 x 10\^9/L
  • Hypertension defined as > 95th age percentile
  • \< 3 months
  • Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 () and P-glycoprotein (P-gp), i.e. all protease inhibitors and the following azole antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically
  • Concomitant use of strong inducers of CYP3A4, i.e. rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Rivaroxaban (BAY59-7939) tablet, OD, Age: 12 - <18

    Subjects aged from 12 - \<18 years were administered with age and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR (immediate-release) tablet once daily (OD) under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kilogram (kg) received a dose (equivalent to 20 milligram \[mg\] in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Active comparator
    Comparator, Age: 12 - <18 years

    Subjects aged from 12 - \<18 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).

    Drug: Active comparator

  • Experimental
    Rivaroxaban (BAY59-7939) tablet, OD, Age: 6 - <12 years

    Subjects aged from 6 - \<12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kg received a dose (equivalent to 20 mg in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Experimental
    Rivaroxaban (BAY59-7939) suspension, BID, Age: 6 - <12 years

    Subjects aged from 6 - \<12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily (BID). Subjects with a body weight of 9 to less than 50 kg received a total daily dose (equivalent to 20 mg in adults) ranging from 6.4 to 15 mg and subjects with a body weight of greater than or equal to 50 kg received a total daily dose of 20 mg.

    Drug: Rivaroxaban (BAY59-7939) suspension

  • Active comparator
    Comparator, Age: 6 - <12 years

    Subjects aged from 6 - \<12 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or INR-adjusted (vitamin K antagonist).

    Drug: Active comparator

Interventions

  • Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.

  • DrugActive comparator

    Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).

  • Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Major and Clinically Relevant Non-Major Bleeding Events

    Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and: * associated with a fall in hemoglobin of 2 gram/decilitre (g/dL) or more, or * leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or * occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or * contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: * medical intervention, or * unscheduled contact (visit or telephone call) with a physician, or * cessation (temporary) of study treatment, or * discomfort for the child such as pain or * impairment of activities of daily life (such as loss of school days or hospitalization).

    Time frame: From start of study drug administration until end of the 30-day treatment period

Secondary outcomes

  1. Number of Subjects With Symptomatic Recurrent Venous Thromboembolism

    The occurrence of recurrent venous thromboembolism was summarized by age group. Symptomatic recurrence of venous thrombosis was documented by the appropriate imaging test.

    Time frame: From start of study drug administration until end of the 30-day treatment period

  2. Number of Subjects With Asymptomatic Deterioration in Thrombotic Burden

    The occurrence of asymptomatic deterioration in thrombotic burden was summarized by age group. Asymptomatic deterioration in thrombotic burden was documented by the appropriate imaging test and the results were classified as normalized, improved, no relevant change, deteriorated, not evaluable or not available.

    Time frame: Repeat imaging at the end of the 30 day treatment period

  3. Change From Baseline in Prothrombin Time at Specified Time Points

    Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.

    Time frame: 0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31

  4. Change From Baseline in Activated Partial Thromboplastin Time at Specified Time Points

    The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway.

    Time frame: 0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31

  5. Anti-factor Xa Values at Specified Time Points

    The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.

    Time frame: 0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31

  6. Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Specified Time Points

    Geometric and percentage geometric coefficient of variation (%CV) were reported.

    Time frame: 0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31

07

Results

Posted Sep 21, 2017

Participant flow

The study was conducted at multiple centers in 10 countries worldwide between 19 February 2013 (first subject first visit) and 01 September 2016 (last subject last visit).

Participant flow — Overall Study
MilestoneRivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsComparator, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 YearsComparator, Age: 6 - < 12 Years
Started111313197
Completed111312197
Not completed00100
Withdrew: Withdrawal by subject00100

Outcome measures

PrimaryNumber of Subjects With Major and Clinically Relevant Non-Major Bleeding Events

Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and: * associated with a fall in hemoglobin of 2 gram/decilitre (g/dL) or more, or * leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or * occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or * contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: * medical intervention, or * unscheduled contact (visit or telephone call) with a physician, or * cessation (temporary) of study treatment, or * discomfort for the child such as pain or * impairment of activities of daily life (such as loss of school days or hospitalization).

Time frame:
From start of study drug administration until end of the 30-day treatment period
Reported as:
Number · Participants
Number of Subjects With Major and Clinically Relevant Non-Major Bleeding Events
ParticipantsRivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsComparator, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 YearsComparator, Age: 6 - < 12 Years
Major bleeding events00000
Clinically relevant non-major bleeding events30010
SecondaryNumber of Subjects With Symptomatic Recurrent Venous Thromboembolism

The occurrence of recurrent venous thromboembolism was summarized by age group. Symptomatic recurrence of venous thrombosis was documented by the appropriate imaging test.

Time frame:
From start of study drug administration until end of the 30-day treatment period
Reported as:
Number · Participants
Number of Subjects With Symptomatic Recurrent Venous Thromboembolism
ParticipantsRivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsComparator, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 YearsComparator, Age: 6 - < 12 Years
Number of Subjects With Symptomatic Recurrent Venous Thromboembolism00000
SecondaryNumber of Subjects With Asymptomatic Deterioration in Thrombotic Burden

The occurrence of asymptomatic deterioration in thrombotic burden was summarized by age group. Asymptomatic deterioration in thrombotic burden was documented by the appropriate imaging test and the results were classified as normalized, improved, no relevant change, deteriorated, not evaluable or not available.

Time frame:
Repeat imaging at the end of the 30 day treatment period
Reported as:
Number · Participants
Number of Subjects With Asymptomatic Deterioration in Thrombotic Burden
ParticipantsRivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsComparator, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 YearsComparator, Age: 6 - < 12 Years
Normalized32241
Improved40894
No relevant change00120
Deteriorated00000
Not evaluable02001
Not available49241
SecondaryChange From Baseline in Prothrombin Time at Specified Time Points

Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.

Time frame:
0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31
Reported as:
Mean · seconds
Change From Baseline in Prothrombin Time at Specified Time Points
secondsRivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years
Day 15: 2 to 4 hours post-dose8.964 ± 3.8229.083 ± 2.5133.147 ± 2.099
Day 15: 6 to 8 hours post-dose4.218 ± 2.9772.817 ± 1.6281.984 ± 1.341
Day 31: 10 to 16 hours post-doseNA ± NANA ± NA0.156 ± 1.155
Day 31: 20 to 24 hours post-dose-0.082 ± 1.020-0.327 ± 1.332NA ± NA
SecondaryChange From Baseline in Activated Partial Thromboplastin Time at Specified Time Points

The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway.

Time frame:
0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31
Reported as:
Mean · seconds
Change From Baseline in Activated Partial Thromboplastin Time at Specified Time Points
secondsRivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years
Day 15: 2 to 4 hours post-dose10.982 ± 4.47012.818 ± 5.2102.995 ± 5.616
Day 15: 6 to 8 hours post-dose6.136 ± 2.6415.900 ± 4.9421.858 ± 4.774
Day 31: 10 to 16 hours post-doseNA ± NANA ± NA-0.483 ± 6.488
Day 31: 20 to 24 hours post-dose1.345 ± 3.1901.240 ± 4.992NA ± NA
SecondaryAnti-factor Xa Values at Specified Time Points

The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.

Time frame:
0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31
Reported as:
Mean · microgram per liter (mcg/L)
Anti-factor Xa Values at Specified Time Points
microgram per liter (mcg/L)Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years
Day 15: pre-dose16.081 ± 6.1368.136 ± 3.06931.553 ± 25.416
Day 15: 2 to 4 hours post-dose185.481 ± 53.326252.853 ± 71.07299.415 ± 54.415
Day 15: 6 to 8 hours post-dose105.223 ± 54.33968.670 ± 32.84577.929 ± 50.074
Day 31: 10 to 16 hours post-doseNA ± NANA ± NA30.927 ± 18.037
Day 31: 20 to 24 hours post-dose16.038 ± 7.6538.409 ± 3.664NA ± NA
SecondaryConcentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Specified Time Points

Geometric and percentage geometric coefficient of variation (%CV) were reported.

Time frame:
0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31
Reported as:
Geometric mean · microgram per liter (mcg/L)
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Specified Time Points
microgram per liter (mcg/L)Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years
Day 15: pre-dose20.4822 ± 40.67267.4367 ± 152.976841.6025 ± 183.6873
Day 15: 2 to 4 hours post-dose219.6933 ± 35.7518240.6319 ± 18.3387119.2201 ± 52.9889
Day 15: 6 to 8 hours post-dose124.6723 ± 49.188296.8051 ± 41.8155100.5992 ± 52.6497
Day 31: 10 to 16 hours post-doseNA ± NANA ± NA43.5223 ± 81.7283
Day 31: 20 to 24 hours post-dose21.3252 ± 43.12749.4654 ± 167.7545NA ± NA

Adverse events

Collected over From start of study drug administration until 30 day post study treatment. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years—0/11 (0%)9/11 (81.8%)
Comparator, Age: 12 - <18 Years—1/13 (7.7%)8/13 (61.5%)
Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years—0/13 (0%)6/13 (46.2%)
Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years—2/19 (10.5%)12/19 (63.2%)
Comparator, Age: 6 - < 12 Years—0/7 (0%)2/7 (28.6%)
Most frequent serious events
Most frequent serious events
EventRivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsComparator, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 YearsComparator, Age: 6 - < 12 Years
Multiple sclerosis relapseNervous system disorders0/111/130/130/190/7
Hypothalamo-pituitary disorderEndocrine disorders0/110/130/131/190/7
Influenza B virus test positiveInvestigations0/110/130/131/190/7
Most frequent other events
Showing 10 of 59
Most frequent other events
EventRivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsComparator, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 YearsComparator, Age: 6 - < 12 Years
MenorrhagiaReproductive system and breast disorders4/110/130/130/190/7
HeadacheNervous system disorders2/110/132/133/190/7
Abdominal painGastrointestinal disorders0/110/132/131/190/7
Abdominal pain upperGastrointestinal disorders0/110/130/131/191/7
DiarrhoeaGastrointestinal disorders1/111/131/130/191/7
VomitingGastrointestinal disorders1/111/130/132/191/7
Chest painGeneral disorders1/110/130/130/191/7
FallInjury, poisoning and procedural complications0/110/130/130/191/7
Vocal cord paralysisNervous system disorders0/110/130/130/191/7
Post thrombotic syndromeVascular disorders0/110/130/130/191/7

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsComparator, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 YearsComparator, Age: 6 - < 12 YearsTotal
Mean15.5 ± 1.214.8 ± 1.08.5 ± 2.18.3 ± 1.99.0 ± 2.011.0 ± 3.7
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 YearsComparator, Age: 12 - <18 YearsRivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 YearsRivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 YearsComparator, Age: 6 - < 12 YearsTotal
Female8756329
Male36813434
08

Study locations

59 sites
  • Little Rock, Arkansas 72202-3500, United States
  • Los Angeles, California 90027-6089, United States
  • Orange, California 92868-3974, United States
  • Chicago, Illinois 60611, United States
  • Indianapolis, Indiana 46202, United States
  • Detroit, Michigan 48201-2196, United States
  • Minneapolis, Minnesota 55404, United States
  • New Hyde Park, New York 11040, United States
  • Cleveland, Ohio 44106-2602, United States
  • Columbus, Ohio 43205-2696, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Houston, Texas 77030, United States
  • Richmond, Virginia 23298, United States
  • Westmead, New South Wales 2145, Australia
  • Parkville, Victoria 3052, Australia
  • South Brisbane, 4101, Australia
  • Linz, Oberösterreich 4020, Austria
  • Graz, Steiermark 8036, Austria
  • Innsbruck, Tirol 6020, Austria
  • Wien, 1090, Austria
  • Edmonton, Alberta T6G 2B7, Canada
  • Hamilton, Ontario L8N 3Z5, Canada
  • Ottawa, Ontario K1H 8L1, Canada
  • Toronto, Ontario M5G 1X8, Canada
  • Quebec, G1V 4G2, Canada
  • BORDEAUX cedex, 33076, France
  • Montpellier Cedex, 34295, France
  • NANTES Cedex 1, 44093, France
  • Paris, 75015, France
  • Paris, 75019, France
  • Rennes Cedex, 35033, France
  • TOULOUSE Cedex 9, 31059, France
  • Freiburg, Baden-Württemberg 79106, Germany
  • Erlangen, Bayern 91054, Germany
  • Frankfurt, Hessen 60590, Germany
  • Dresden, Sachsen 01307, Germany
  • Lübeck, Schleswig-Holstein 23538, Germany
  • Berlin, 13353, Germany
  • Beer Sheva, 8410101, Israel
  • Haifa, 3109601, Israel
  • Jerusalem, 9112001, Israel
  • Petach Tikva, 4920235, Israel
  • Ramat Gan, 5262000, Israel
  • Genova, Liguria 16147, Italy
  • Milano, Lombardia 20122, Italy
  • Pavia, Lombardia 27100, Italy
  • Torino, Piemonte 10126, Italy
  • Bari, Puglia 70124, Italy
  • Padova, Veneto 35128, Italy
  • Amsterdam, 1081 HV, Netherlands
  • Amsterdam, Netherlands
  • Nijmegen, 6525 GA, Netherlands
  • Rotterdam, 3015 GJ, Netherlands
  • Utrecht, 3584 CX, Netherlands
  • Basel, Basel-Stadt 4056, Switzerland
  • St. Gallen, Sankt Gallen 9006, Switzerland
  • Bern, 3010, Switzerland
  • Luzern, 6000, Switzerland
  • Zürich, 8032, Switzerland
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Sep 2016, 42 months.

Results were first posted in Sep 2017, 1 year after primary completion.

Of 16 phase 2 interventional studies under Venous Thrombosis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2012
First posted
Sep 13, 2012
StartActual
Feb 19, 2013
Primary completionActual
Sep 1, 2016
CompletionActual
Sep 1, 2016
Results first posted
Sep 21, 2017
Last update
Sep 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01684423
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 13, 2012
Start date
Feb 19, 2013
Primary completion
Sep 1, 2016
Completion
Sep 1, 2016
Results posted
Sep 21, 2017
Last update
Sep 21, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion